TCDA stock forecast
Our latest prediction for Tricida, Inc.'s stock price was made on the Feb. 3, 2020 when the stock price was at 37.26$.
In the short term (2weeks), TCDA's stock price should underperform the market by -2.99%. During that period the price should oscillate between -10.00% and +9.67%.
In the medium term (3months), TCDA's stock price should underperform the market by -6.04%. During that period the price should oscillate between -38.13% and +24.84%.Get email alerts
About Tricida, Inc.
Tricida, Inc. is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.31$ per share.
The book value per share is 5.20$
Three months stock forecastFeb. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|